StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Nimetazepam

HCID 4496
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
2011-67-8
Standard-SMILES
CN1C(=O)CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc21
InChIKey
GWUSZQUVEVMBPI-UHFFFAOYSA-N
Summenformel
C16H13N3O3
Durchschnittliche Molmasse
295,29 g/mol
Monoisotopische Masse
295,09569129

Überblick

Nimetazepam is a nitrazepam which is substituted at positions 1 by a methyl group. It is used as an anticonvulsant and as a hypnotic for the short-term management of insomnia. It has a role as an anticonvulsant, a sedative, a GABA modulator and an antispasmodic drug. It is a 1,4-benzodiazepinone and a C-nitro compound. It is functionally related to a nitrazepam.

Namen und Bezeichner

Bevorzugter Name
Nimetazepam
IUPAC
1-methyl-7-nitro-5-phenyl-3H-1,4-benzodiazepin-2-one
Lokaler Name
Nimetazepam
Englischer Name
Nimetazepam
Summenformel
C16H13N3O3
Molmasse
295.29

Namen und Synonyme

nimetazepam2011-67-81-MethylnitrazepamEriminMethylnitrazepamNimetazepamum1,3-Dihydro-1-methyl-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-oneRo 5-3453S 1530DTXSID60233691-methyl-7-nitro-5-phenyl-3H-1,4-benzodiazepin-2-one1-Methyl-5-phenyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
Weitere Namen anzeigen
EliminHypnonro5-3453NimetazamN-MethylmogadonNimetazepam (CRM)Nimetazepam solution
1-Methyl-7-nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-oneS-1530CHEBI:31912DTXCID3033694532264KW61-methyl-7-nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-oneRefChem:854155217-931-5

Datenbank-Bezeichner

CAS
2011-67-8
PubChem CID
4496
DTXSID
DTXSID6023369
ChEMBL

Eigenschaften

Berechnete Struktureigenschaften

XLogP
2,2
Polarare Oberfläche (TPSA)
78,5 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
1
Schwere Atome
22
Formalladung
0
Komplexität
480

Experimentelle und physikochemische Eigenschaften

Drugs · 3 Einträge

DEA NFLIS-Drug Category -> Benzodiazepines

DEA Schedule IV Controlled Substance -> Depressants

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

LogP2.16
Collision Cross Section169.7 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated]

Physikochemische Eigenschaften

Schmelzpunkt
156.5 · 156.5-157.5°
Siedepunkt
436.98 °C · 436.98°C (rough estimate)
Dichte
1.1952 · 1.1952 (rough estimate)
Brechungsindex
1.65 · 1.6500 (estimate)
Flammpunkt
9 ℃ · 9℃
storage temp.
-20 °C · -20°C
Löslichkeit
Chloroform (Slightly), Methanol (Slightly)
Aggregatzustand
Solid

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P273, P301+P317, P330, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory InformationDEA schedule IV controlled substance
Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxikologische Informationen

Treatment · 1 Eintrag

General supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. Flumazenil (Anexate) is a competitive benzodiazepine receptor antagonist that can be used as an antidote for benzodiazepine overdose. In particular, flumazenil is very effective at reversing the CNS depression associated with benzodiazepines but is less effective at reversing respiratory depression. Its use, however, is controversial as it has numerous contraindications. It is contraindicated in patients who are on long-term benzodiazepines, those who have ingested a substance that lowers the seizure threshold, or in patients who have tachycardia or a history of seizures. As a general rule, medical observation and supportive care are the mainstay of treatment of benzodiazepine overdose. Although benzodiazepines are absorbed by activated charcoal, gastric decontamination with activated charcoal is not beneficial in pure benzodiazepine overdose as the risk of adverse effects often outweigh any potential benefit from the procedure. It is recommended only if benzodiazepines have been taken in combination with other drugs that may benefit from decontamination. Gastric lavage (stomach pumping) or whole bowel irrigation are also not recommended.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

N - Nervous system

QN - Nervous system

MeSH Pharmacological Classification · 4 Einträge

Drugs used to prevent SEIZURES or reduce their severity.

Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.

Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.

Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here.

Anwendungen

VerwendenSedative, hypnotic. Controlled substance.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

HydrogenchloridDiethylether-BortrifluoridChromtrioxid

Ergänzende Hinweise

DefinitionChEBI: A nitrazepam which is substituted at positions 1 by a methyl groups. It is used as an anticonvulsant and as a hypnotic for the short-term management of insomnia.

Zugehörige Reaktionen

6
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 187005
HRID 187005als Edukt
Reaktionsgleichung von HRID 441941
HRID 441941als Edukt
Reaktionsgleichung von HRID 865711
HRID 865711als Edukt
Reaktionsgleichung von HRID 1729600
HRID 1729600als Edukt
Reaktionsgleichung von HRID 1729968
HRID 1729968als Produkt
Reaktionsgleichung von HRID 2342364
HRID 2342364als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
CHEMBL13341
ChEBI
CHEBI:31912
UNII
4532264KW6
EC Number
217-931-5
Nikkaji
J4.431H
pka
2.53 · pKa 2.53(EtOH/H2O,t =25,Iundefined) (Uncertain)
Farbe
Light Yellow to Dark Yellow
CAS Datenbank
2011 · 2011-67-8(CAS DataBase Reference)
NIST chemische Informationen
Nimetazepam(2011-67-8)
Toxicity Summary · 1 Eintrag

Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

Sicherheitsdaten

wgk
1
ridadr
UN1230 - class 3 - PG 2 - Methanol, solution
risk_code
11-23/24/25-39/23/24/25
Toxizität
LD50 in male, female mice, rats (mg/kg): 910, 750, 1150, 970 orally; 970, 840, 970, 980 i.p.; 1500, 1500, 1000, 1000 s.c. (Sakai)
hazard_code
F,T
safety_code
16-36/37-45
DEA Controlled Substances
CSCN: 2837CSA SCH: Schedule IVNARC: No